In-vitro susceptibility of linezolid against methicillin resistant Staphylococcus aureus at a tertiary care hospital in Pakistan by Ali Khalid et al.
203
Correspondence: Ali Khalid, Specialist Pathologist, 
Clinical Microbiologist, Najran University Hospital, Najran. Kingdom of Saudi Arabia     Email: dr-alikhalid@hotmail.com 
Received: 01.05.2013, Accepted: 07.08.2013 
Copyright © Journal of Microbiology and Infectious Diseases 2013, All rights reserved
Journal of Microbiology and Infectious Diseases /  2013; 3 (4): 203-206
JMID   doi: 10.5799/ahinjs.02.2013.04.0109
BRIEF REPORT
In-vitro susceptibility of linezolid against methicillin resistant 
Staphylococcus aureus at a tertiary care hospital in Pakistan
Ali Khalid, Javaid Usman, Umaira Faiz, Fatima Kaleem, Afreenish Hassan, Maria Omair
Microbiology Department, Army Medical College, National University of Sciences and Technology, Islamabad 44000, Pakistan
ABSTRACT
Objective: Methicillin resistant Staphylococcus aureus is a major nosocomial pathogen causing significant morbidity 
and mortality. The aim of this study was to evaluate the in vitro activity of linezolid against methicillin-resistant S. aureus.
Methods: This was a descriptive study carried out at the Department of Microbiology, Army Medical College Rawalpindi 
from January to July 2010. The in vitro minimum inhibitory concentration of linezolid was determined against 74 strains 
of methicillin-resistant S. aureus by using the Epsilon- test (E-test) method (AB Biodisk, Sweden). Methicillin-resistant S. 
aureus was isolated from routine clinical specimens using standard microbiological procedures. Cefoxitin (30 μg) disk 
was used for detection of methicillin-resistant strains of Staphylococcus aureus.
Results: Seventy-four isolates of methicillin-resistant S. aureus were obtained from various clinical samples. The major-
ity of samples were from the pus followed by nasobronchial lavage, urine and vaginal swabs. All the isolates were highly 
susceptible to linezolid with minimum inhibitory concentration range of 0.023 - 0.75 mg/dL having MIC50 0.25 and 
MIC90 0.5 mg/dL respectively.
Conclusion: Linezolid shows good in vitro activity against methicillin-resistant Staphylococcus aureus. J Microbiol Infect 
Dis 2013;3(4): 203-206
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Pakistan’da bir üçüncü basamak hastanede metisilin dirençli Staphylococcus aureus’a karşı 
in-vitro linezolid duyarlılığı
ÖZET
Amaç: Metisilin dirençli Staphylococcus aureus belirgin morbidite ve mortaliteye neden olan önemli bir nozokomiyal 
patojendir. Bu çalışmanın amacı, metisilin dirençli S. aureus’a karşı linezolidin in vitro etkinliğini değerlendirmektir.
Yöntemler: Army Medical College Rawalpindi Mikrobiyoloji Anabilim Dalında, Temmuz-Ocak 2010’da yürütülen tanım-
layıcı bir çalışmadır. Linezolid için in vitro minimum inhibe edici konsantrasyon, metisiline dirençli 74 S. aureus türü için 
Epsilon- test (E-test) metodu (AB Biodisk, İsveç) kullanılarak belirlendi. Metisiline dirençli S. aureus standart mikrobiyo-
lojik yöntemler kullanılarak rutin klinik örneklerden izole edilmiştir. Metisilin dirençli S. aureus suşlarının saptanması için 
sefoksitin (30 µg) disk kullanılmıştır. 
Bulgular: Metisilin dirençli 74 S. aureus izolatı çeşitli klinik örneklerden elde edilmiştir. Numunelerin çoğunluğu na-
sobronchial lavaj, idrar ve vajinal sürüntülerden alınan püydü. 
Tüm izolatların 0.023-0.75 mg/dL minimum inhibitör konsantrasyon aralığında sırasıyla MIC50 0.25 ve MIC90 0.5 mg/
dL ile linezoilde son derece duyarlı idi.
Sonuç: Linezolid metisiline dirençli S. aureus karşı i in vitro iyi aktivite gösterir.
Anahtar kelimeler: Linezolid, metisilin direnci, minimum inhibitör konsantrasyon, Staphylococcus aureus, vankomisinKhalid A, et al. MIC values of Linezolid against methicillin-resistant S. aureus 204
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INTRODUCTION
Over the last two decades, the increasing incidence 
of methicillin-resistant Staphylococci has caused 
significant clinical concern worldwide. Methicillin re-
sistance in S. aureus (MRSA) is also associated with 
resistance to several commonly used antimicrobial 
agents such as the macrolides, lincosamides, qui-
nolones, trimethoprim-sulfamethoxazole and ami-
noglycosides.1 During the past 15 years, the appear-
ance and world-wide spread of epidemic clones of 
MRSA have caused major therapeutic problems in 
many hospitals, as well as diversion of considerable 
resources to attempts at controlling their spread.2 
With the increasing incidence of multi-drug resistant 
Staphylococci and the emergence of resistance to 
glycopeptides in MRSA worldwide, therapeutic op-
tions are becoming increasingly limited.
Resistance  to  all  the  available  antibiotics 
against Staphylococcus except vancomycin has 
been  reported.3 The undesirable side effects of 
vancomycin make it unsuitable in a subset of pa-
tients. After the emergence of vancomycin resistant 
Enterococci, it was feared that this resistance may 
spread to Staphylococci which proved to be the 
case when low level vancomycin resistance was 
reported  in  Staphylococci.4 High level resistance 
against vancomycin was reported soon after,5,6 
making the treatment of infections by this organism 
a therapeutic dilemma. 
Linezolid  is  the  first  approved  member  of  a 
new generation of antibiotics, synthetic oxazolidi-
none. These are broad spectrum antibiotics active 
against a wide variety of Gram-positive organisms, 
including methicillin resistant Staphylococci, peni-
cillin resistant Pneumococci and the vancomycin 
resistant  Enterococci.7-9 Linezolid has a bacterio-
static action predominantly by binding to the 50S 
ribosomal subunit and ultimately inhibiting bacterial 
protein synthesis by interfering with the formation 
of the initiation complex in bacterial translation sys-
tems.10 As this agent possesses a novel structure 
and unique mechanism of action, it does not display 
cross-resistance with other classes of antimicrobial 
agents.1 The Clinical and Laboratory Standards In-
stitute11 (CLSI) has established indications for line-
zolid use and breakpoint interpretive criteria of ≤2 
mg/L as susceptible for Streptococci or Enterococci 
and ≤4 mg/l for Staphylococci.
Linezolid therapy was shown to be successful 
for MRSA infection in patient with a severe allergic 
reaction to vancomycin.12 Plasma concentrations of 
intravenous and oral linezolid are equivalent, with 
an  average  concentration  exceeding  the  MIC  for 
susceptible pathogens throughout the 12 h dosing 
interval.10 The excellent oral bioavailability of line-
zolid and a much lower cost as compared to van-
comycin and teicoplanin makes it an extremely at-
tractive antibiotic for the treatment of suspected or 
confirmed Staphylococcal infections.
The objective of the study was to assess the 
MIC of Linezolid against MRSA to highlight the ef-
ficacy of this therapeutic agent against this deadly 
organism in our setting.
METHODS
The study was carried out in the Department of Mi-
crobiology at Army Medical College, National Uni-
versity  of  Sciences  and  Technology,  Rawalpindi, 
Pakistan. A total of 74 clinical strains of methicillin-
resistant  S. aureus were collected from January 
2010 to July 2010 from patients attending at the 
Military Hospital, Rawalpindi. These isolates were 
identified by conventional methods 11 including col-
ony morphology and hemolysis on 5 per cent sheep 
blood agar, Gram’s staining, catalase production, 
DNAse and coagulase test. Methicillin resistance of 
isolated Staphylococci was detected by agar disk-
diffusion method (Kirby-Bauer) using a 30 μg cefox-
itin disc according to the guidelines established by 
CLSI.
Staphylococcal isolates were sub cultured on 
blood agar and after overnight incubation at 37 0C; 
three to five morphologically similar colonies were 
then emulsified in sterile isotonic saline. The sus-
pension was adjusted to 0.5 McFarland standards 
(106 CFU/ml). In order to determine the activity of li-
nezolid, Mueller-Hinton agar plates were inoculated 
by swabbing of the surface with the suspension of 
organisms. E-test (AB-Biodisk, Sweden) strips con-
taining linezolid (range 0.016-256 mg/L) were ap-
plied onto the surface of the agar. After incubation 
for 24 h at 37°C in ambient air, the MIC was read 
directly from the intersection of the inhibition zone 
with the test strip MIC scale. Results of MIC were 
interpreted according to the breakpoints given by 
CLSI 2009 where MIC ≤4 mg/L was taken as sus-
ceptible.  S. aureus ATCC  29213  reference  strain 
was used as control. Results were interpreted by 
using SPSS version 17.0 and the quantitative vari-
ables like the MIC50 and MIC90 were calculated. 
RESULTS
The activity of linezolid against the 74 MRSA strains 
tested is shown in the table (Table 1). All the 74 iso-
lates were found to be highly susceptible to linezolid Khalid A, et al. MIC values of Linezolid against methicillin-resistant S. aureus 205
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(MICs <4.0 mg/L). The range of minimum inhibitory 
concentration for the strains was 0.023-0.75 mg/L 
with MIC50 and MIC90 of 0.25 and 0.5 mg/L re-
spectively. Majority of the tested strains were iso-
lated from the pus samples [44 (60%)]) followed by 
nasobronchial  lavage  [18  (24%)],  urine  [8  (10%)] 
and vaginal swabs [4 (6%)] . 
Table 1. Minimum inhibitory concentrations of linezolid against MRSA ( n=74 )
Isolates
(n)
Antimicrobial
agent
% of isolates Susceptible at MIC (mg/L) Concentrations (mg/L)
0.016 0.023 0.032 0.064 0.094 0.125 0.19 0.25 0.38 0.50 0.75 1 2 Range MIC50 MIC90
MRSA Linezolid   -  2 2 6 8 4 12 26 24 12 4  -  -  0.023-0.75 0.25 0.5
Figure 1. Linezolid E-strip
DISCUSSION
Methicillin-resistant S. aureus is a major nosocomial 
pathogen causing significant morbidity and mortal-
ity. Methicillin resistant Staphylococcus has become 
a global problem limiting the treatment modalities 
to a large extent. Once the β-lactam fails, the main 
option against methicillin-resistant Staphylococ-
cus (MRSA) infections is the use of glycopeptides, 
vancomycin and teicoplanin.13 However, the emer-
gence  of  clinical  infection  due  to  MRSA  with  de-
creased susceptibility to vancomycin is a recent and 
certainly worrying fact. Treatment of Staphylococ-
cus infections has become more difficult because 
of multidrug-resistant strains that are resistant to ≥3 
antibiotics tested at the same time.14
Parenteral vancomycin has so far been the 
only reliable treatment option in many cases of se-
rious MRSA infections.15 However, S. aureus with 
intermediate resistance to vancomycin [VISA] (MIC 
8  mg/L),  was  first  reported  from  Japan  and  then 
from the United States. This has given the cause 
for alarm in the health care community.16,17 In addi-
tion to that, vancomycin-resistant Staphylococcal 
strains (VRSA) have been reported from Brazil, Jor-
dan and India.18-20 Shajari et al reported that 18.4% 
of the methicillin-resistant S. aureus strains were 
resistant to vancomycin.21 This situation warranted 
the urgent search for new, safe and reliable agents 
for the treatment of infections caused by multidrug-
resistant Gram-positive pathogens. Therefore, the 
development and subsequent approval of linezolid 
for clinical use against Gram-positive bacteria is a 
great achievement. 
The excellent in vitro activity of linezolid found 
in this study agrees with the findings of previous 
studies,22 although the MICs are slightly lower than 
those  reported  by Afşar  et  al.23 A  previous  study 
done in Lahore, Pakistan also had similar results.13 
Mouton and Jansz reported that MIC90 of 1.5 mg/L 
for linezolid for S. aureus and cross-resistance with 
other antibiotics was not detected in their study.24 
Cuevas et al studied 866 Staphylococcal isolates 
(463 S. aureus strains) from 1986 to 2006 in Spain 
and found that only one strain was linezolid-resis-
tant.25  Linezolid  has  an  acceptable  safety  profile 
for both intravenous as well as oral administration 
and has proven to be effective in the treatment of 
infections due to methicillin-resistant Staphylococ-
cal species in critically ill patients. It is a good alter-
native to vancomycin in the acute renal injury pa-
tients.16 All of these data, together with the results 
of this study, suggest that linezolid could be useful 
for the treatment of infections due to methicillin-re-
sistant S. aureus.
In conclusion, this study demonstrates that li-
nezolid has an excellent in vitro activity against 
methicillin-resistant S. aureus. The MRSA was most 
prevalent in the pus samples and the MIC90 was 0.5 
mg/dL. This drug is a promising therapeutic option 
in an era of rapidly growing antibiotic resistance.Khalid A, et al. MIC values of Linezolid against methicillin-resistant S. aureus 206
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